Core Insights - Omnicell, Inc. reported a significant increase in adjusted earnings per share (EPS) for Q4 2024, reaching 60 cents, an 81.8% year-over-year surge, surpassing the Zacks Consensus Estimate by 5.2% [1][2] - Total revenues for Q4 2024 were $306.9 million, reflecting an 18.6% increase year-over-year and exceeding the Zacks Consensus Estimate by 3.3% [3] - The company anticipates total revenues for 2025 to be between $1.105 billion and $1.155 billion, with adjusted EPS expected in the range of $1.65 to $1.85 [7] Financial Performance - The GAAP EPS for Q4 2024 was 34 cents, compared to a loss of 32 cents in the same period last year [2] - For the full year, adjusted earnings were $1.71 per share, down 10.4% from the previous year [2] - Gross profit for Q4 increased by 34.5% year-over-year to $141.8 million, with a gross margin expansion of 547 basis points to 46.2% [5] Revenue Breakdown - Product revenues in Q4 declined by 25.1% year-over-year to $182.3 million, while service and other revenues increased by 10.1% to $124.6 million [4] - Total revenues for the full year 2024 were reported at $1.11 billion, down 3% from the previous year [3] Cash Flow and Financial Position - At the end of Q4 2024, Omnicell had cash and cash equivalents of $369.2 million, down from $468 million at the end of Q4 2023 [6] - Cumulative cash flow from operating activities at the end of Q4 was $187.7 million, compared to $181.1 million in the prior year [6] Strategic Developments - The company achieved notable wins in Q4, including service renewals and expansions with major medical centers and new contracts for specialty pharmacy programs [10] - The XT Amplify innovation program continues to gain traction, contributing to the company's growth [10] Market Reaction - Following the earnings announcement on February 6, OMCL shares rose by 1.9%, closing at $40.16 [3]

Investor Presentation February 6, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "belie ...

Omnicell, Inc. (NASDAQ:OMCL) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President and Chief Executive Officer Nchacha Etta - Executive Vice President and Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Jessica Datson - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Scott Schoenhaus - KeyBanc Capital Markets Stan Berenshteyn - Wells Fa ...

Omnicell (OMCL) Q4 2024 Earnings Call February 06, 2025 08:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor RelationsRandall Lipps - Founder, Chairman, President and CEONchacha Etta - Executive VP & CFOScott Schoenhaus - Managing Director Conference Call Participants Allen Lutz - Senior Equity Research AnalystJessica Tassan - Senior Equity Research AnalystMatthew Hewitt - Senior Research AnalystStan Berenshteyn - Equity Research AnalystDavid Larsen - Analyst, Managing Director ...

Omnicell (OMCL) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.41 per share when it actually produced earnings of $0.56, delivering a surprise of 36.59%.Over the last four quarters, the company ha ...

Financial Performance - Total revenues for Q4 2024 were $307 million, an increase of $48 million or 19% year-over-year[3]. - Total revenues for the fiscal year 2024 were $1.112 billion, a decrease of $35 million or 3% compared to 2023[3]. - Total GAAP net income for Q4 2024 was $16 million, or $0.34 per diluted share, compared to a GAAP net loss of $14 million in Q4 2023[4]. - Total non-GAAP net income for Q4 2024 was $28 million, or $0.60 per diluted share, compared to $15 million in Q4 2023[5]. - Net income for the year ended December 31, 2024, was $12,531,000, compared to a net loss of $20,371,000 in 2023[44]. - Operating cash flow for the year ended December 31, 2024, was $187,722,000, slightly up from $181,094,000 in 2023[44]. - Total revenues for Q4 2024 reached $306,879,000, a 18.6% increase from $258,847,000 in Q4 2023[40]. - Product revenues were $182,271,000 in Q4 2024, up from $145,655,000 in Q4 2023, representing a 25.1% growth[40]. - Service revenues increased to $124,608,000 in Q4 2024, compared to $113,192,000 in Q4 2023, marking a 10.8% rise[40]. - Gross profit for Q4 2024 was $141,761,000, a significant increase from $105,404,000 in Q4 2023, reflecting a 34.4% improvement[40]. - GAAP gross profit for Q4 2024 was $141,761 thousand, up from $105,404 thousand in Q4 2023, representing a 34.4% increase[46]. - Non-GAAP gross profit for Q4 2024 was $145,478 thousand, compared to $112,797 thousand in Q4 2023, reflecting a 29.0% increase[46]. - GAAP net income for Q4 2024 was $15,842 thousand, a significant recovery from a net loss of $14,375 thousand in Q4 2023[48]. - Non-GAAP net income for Q4 2024 reached $28,340 thousand, up from $15,013 thousand in Q4 2023, indicating an increase of 88.7%[48]. - Non-GAAP EBITDA for Q4 2024 was $46,424 thousand, compared to $23,742 thousand in Q4 2023, marking a 95.5% increase[50]. - Non-GAAP free cash flow for Q4 2024 was $42,747 thousand, up from $26,042 thousand in Q4 2023, representing a 64.2% increase[50]. - GAAP operating expenses for Q4 2024 were $129,365 thousand, slightly higher than $128,769 thousand in Q4 2023, with a decrease in operating expenses as a percentage of total revenues from 49.7% to 42.2%[46]. - Non-GAAP operating expenses for Q4 2024 were $113,019 thousand, compared to $103,459 thousand in Q4 2023, with a decrease in percentage of total revenues from 40.0% to 36.8%[46]. - The company reported a GAAP operating income of $12,396 thousand for Q4 2024, a recovery from a loss of $23,365 thousand in Q4 2023[46]. - Non-GAAP operating margin improved to 10.6% in Q4 2024 from 3.6% in Q4 2023, indicating enhanced operational efficiency[46]. Future Projections - For 2025, the company projects total revenues between $1.105 billion and $1.155 billion[21]. - The company anticipates long-term growth and consistent GAAP profitability, despite potential risks such as unfavorable economic conditions and competition in the medication management market[27]. - The company is focused on transforming pharmacy and nursing care through outcomes-centric solutions, aiming to deliver clinical and business outcomes across all care settings[24]. - The company is investing in research and development to enhance existing products and develop new solutions, aiming to meet evolving market demands[27]. - The company’s financial guidance includes expectations for product bookings and annual recurring revenue, indicating a focus on sustainable growth[27]. Debt and Cash Management - As of December 31, 2024, cash and cash equivalents were $369 million, with total debt of $341 million[15]. - The company issued $172.5 million in convertible senior notes due 2029 and repurchased $400 million in convertible senior notes due 2025[20]. - Cash and cash equivalents decreased to $369,201,000 as of December 31, 2024, down from $467,972,000 in 2023[42]. - Total assets decreased to $2,120,960,000 in 2024 from $2,226,878,000 in 2023[42]. - Total liabilities decreased to $877,647,000 in 2024 from $1,037,924,000 in 2023[42]. - Omnicell's substantial debt may affect its financial flexibility and access to capital, posing a risk to its growth strategy[27]. Risks and Challenges - The company faces risks related to cybersecurity, including previous ransomware incidents, which could impact its operations and financial performance[27]. - The company is committed to maintaining relationships with its pharmacy customers while navigating regulatory and market challenges[27]. - The company emphasizes the importance of non-GAAP financial measures, which include non-GAAP gross profit, operating expenses, and EBITDA, to provide a clearer view of its core operating performance[28]. - The company expects to continue reporting non-GAAP financial measures, which may differ from GAAP results, highlighting the importance of understanding both[36]. - Omnicell's non-GAAP EBITDA is adjusted for various items, including share-based compensation and acquisition-related expenses, to reflect the company's ongoing operations more accurately[30]. Bookings and Backlog - Total bookings for the year ended December 31, 2024, were $923 million, an increase of 8% year-over-year[8]. - Total backlog as of December 31, 2024, was $1.201 billion, up from $1.143 billion in 2023[9]. New Product Launch - The company announced the launch of OmniSphere, a cloud-native software workflow engine aimed at enhancing medication management[17].

Omnicell (OMCL) is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s Advanced Services offerings is highly encouraging to sustain growth in the upcoming quarters. Efforts to expand into more overseas markets instill optimism. However, adverse macroeconomic challenges and fierce rival pressure could hurt Omnicell’s performance.Currently sporting a Zacks Rank #1 (Strong Buy), OMCL st ...

The market expects Omnicell (OMCL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Omnicell, Inc. (OMCL) has witnessed strong momentum in the past year. Shares of the company have risen 26.2% against 15.7% decline of the industry. The S&P 500 composite has increased 24.2%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Omnicell develops and markets end-to-end automation solutions for the medication-use process. The company's products enable care providers to improve patient saf ...

Core Viewpoint - Omnicell (OMCL) shows a positive earnings outlook, with analysts raising their earnings estimates, indicating potential for continued stock momentum [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions reflects growing analyst optimism about Omnicell's earnings prospects, which is expected to influence the stock price positively [2]. - The current-quarter earnings estimate is $0.57 per share, representing a 72.73% increase from the previous year, with a 9.57% increase in consensus estimates over the last 30 days [5]. - For the full year, the expected earnings are $1.68 per share, showing a year-over-year decline of 12.04%, but the consensus estimate has increased by 10.67% due to positive revisions [6]. Zacks Rank - Omnicell has achieved a Zacks Rank 1 (Strong Buy), supported by strong agreement among analysts in raising earnings estimates, which historically correlates with stock outperformance [3][7]. - Stocks with Zacks Rank 1 and 2 have shown significant outperformance compared to the S&P 500 [7]. Stock Performance - The stock has gained 6.6% over the past four weeks, driven by solid estimate revisions, suggesting that it may be a good addition to investment portfolios [8].